Cannabidiol specialist GW Pharmaceuticals (Nasdaq: GWPH) has revealed it plans to charge around $32,500 per year for Epidiolex (cannabidiol), a new oral therapy for certain forms of epilepsy, in the USA. Shares in the UK-based firm are up over 3% for the week.
On a conference call with investors, the firm reportedly explained the price would enable Epidiolex to be comparable with other epilepsy products on the market.
Epidiolex is the first US Food and Drug Administration-approved therapy based on cannabis. While the firm won the green light to market the product earlier this year, it is awaiting approval from the US Drug Enforcement Administration (DEA), which is investigating its potential for abuse.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze